Download PDF
Semin Respir Crit Care Med 2023; 44(02): 252-259
DOI: 10.1055/s-0042-1759882
Review Article

Clinical Relevance of Fungi in Cystic Fibrosis

Carsten Schwarz
1   Department of Education and Research, Health and Medical University-Health and Medical University Potsdam, Potsdam, Germany
2   Division of Cystic Fibrosis, Cystic Fibrosis Center West Brandenburg, Postdam, Germany
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

In cystic fibrosis, a new era has started with the approval and use of highly effective cystic fibrosis transport regulator (CFTR) modulator therapy. As pulmonary function is increasing and exacerbation rate significantly decreases, the current meaning of fungal pulmonary diseases is questioned. During the past couple of decades, several studies have been conducted regarding fungal colonization and infection of the airways in people with cystic fibrosis. Although Aspergillus fumigatus for filamentous fungi and Candida albicans for yeasts remain by far the most common fungal species in patients with cystic fibrosis, the pattern of fungal species associated with cystic fibrosis has considerably diversified recently. Fungi such as Scedosporium apiospermum or Exophiala dermatitidis are recognized as pathogenic in cystic fibrosis and therefore need attention in clinical settings. In this article, current definitions are stated. Important diagnostic steps are described, and their usefulness discussed. Furthermore, clinical treatment strategies and recommendations are named and evaluated. In cystic fibrosis, fungal entities can be divided into different subgroups. Besides colonization, allergic bronchopulmonary aspergillosis, bronchitis, sensitization, pneumonia, and aspergilloma can occur as a fungal disease entity. For allergic bronchopulmonary aspergillosis, bronchitis, pneumonia, and aspergilloma, clear indications for therapy exist but this is not the case for sensitization or colonization. Different pulmonary fungal disease entities in people with cystic fibrosis will continue to occur also in an era of highly effective CFTR modulator therapy. Whether the percentage will decrease or not will be the task of future evaluations in studies and registry analysis. Using the established definition for different categories of fungal diseases is recommended and should be taken into account if patients are deteriorating without responding to antibiotic treatment. Drug–drug interactions, in particular when using azoles, should be recognized and therapies need to be adjusted accordingly.

Keywords

cystic fibrosis transport regulator - fungal colonization - cystic fibrosis


Publication History

Article published online:
06 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Jain R, Mall M, Drevine P. et al. Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF and F508del/minimal function genotypes. Pediatr Pulmonol 2019; 54: 346-347
    PubMedGoogle Scholar
  • 2 Middleton PG, Mall MA, Dřevínek P. et al; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381 (19) 1809-1819
    CrossrefPubMedGoogle Scholar
  • 3 Ridley K, Condren M. Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J Pediatr Pharmacol Ther 2020; 25 (03) 192-197
    PubMedGoogle Scholar
  • 4 Pihet M, Carrere J, Cimon B. et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis – a review. Med Mycol 2009; 47 (04) 387-397
    CrossrefPubMedGoogle Scholar
  • 5 Düesberg U, Wosniok J, Naehrlich L, Eschenhagen P, Schwarz C. Risk factors for respiratory Aspergillus fumigatus in German cystic fibrosis patients and impact on lung function. Sci Rep 2020; 10 (01) 18999
    CrossrefPubMedGoogle Scholar
  • 6 Schwarz C, Bouchara J-P, Buzina W. et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia 2018; 183 (01) 7-19
    CrossrefPubMedGoogle Scholar
  • 7 Singh A, Ralhan A, Schwarz C, Hartl D, Hector A. Fungal pathogens in CF airways: Leave or treat?. Mycopathologia 2018; 183 (01) 119-137
    CrossrefPubMedGoogle Scholar
  • 8 Bouchara J-P, Symoens F, Schwarz C, Chaturvedi V. Fungal respiratory infections in cystic fibrosis (CF): recent progress and future research agenda. Mycopathologia 2018; 183 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 9 Schwarz C, Vandeputte P, Rougeron A. et al; ECMM/ISHAM Working Group Fungal Respiratory Infections in Cystic Fibrosis (Fri-CF). Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. Med Mycol 2018; 56 (suppl 1): 42-59
    CrossrefPubMedGoogle Scholar
  • 10 Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens?. Int J Biochem Cell Biol 2014; 52: 161-173
    CrossrefPubMedGoogle Scholar
  • 11 Ramirez-Garcia A, Pellon A, Rementeria A. et al. Scedosporium and lomentospora: an updated overview of underrated opportunists. Med Mycol 2018; 56 (suppl 1): 102-125
    CrossrefPubMedGoogle Scholar
  • 12 Bouchara J-P, Hsieh HY, Croquefer S. et al. Development of an oligonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J Clin Microbiol 2009; 47 (01) 142-152
    CrossrefPubMedGoogle Scholar
  • 13 Middleton PG, Chen SCA, Meyer W. Fungal infections and treatment in cystic fibrosis. Curr Opin Pulm Med 2013; 19 (06) 670-675
    CrossrefPubMedGoogle Scholar
  • 14 Roehmel JF, Tintelnot K, Bernhardt A, Seibold M, Staab D, Schwarz C. Arxula adeninivorans causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. Lancet 2015; 385 (9976): 1476
    CrossrefPubMedGoogle Scholar
  • 15 Zalar P, Novak M, de Hoog GS, Gunde-Cimerman N. Dishwashers – a man-made ecological niche accommodating human opportunistic fungal pathogens. Fungal Biol 2011; 115 (10) 997-1007
    CrossrefPubMedGoogle Scholar
  • 16 Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 1992; 151 (05) 344-346
    CrossrefPubMedGoogle Scholar
  • 17 Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet 1990; 336 (8708): 188-189
    CrossrefPubMedGoogle Scholar
  • 18 Hickey PW, Sutton DA, Fothergill AW. et al. Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 2009; 47 (10) 3091-3097
    CrossrefPubMedGoogle Scholar
  • 19 Hirschi S, Letscher-Bru V, Pottecher J. et al. Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol 2012; 50 (12) 4168-4170 [Internet]
    CrossrefPubMedGoogle Scholar
  • 20 Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45 (08) 764-771
    CrossrefPubMedGoogle Scholar
  • 21 Eschenhagen P, Grehn C, Schwarz C. Prospective evaluation of Aspergillus fumigatus-specific IgG in patients with cystic fibrosis. Front Cell Infect Microbiol 2021; 10: 602836
    CrossrefPubMedGoogle Scholar
  • 22 Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999; 116 (03) 639-646
    CrossrefPubMedGoogle Scholar
  • 23 Baxter CG, Dunn G, Jones AM. et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013; 132 (03) 560-566.e10
    CrossrefPubMedGoogle Scholar
  • 24 Brandt C, Roehmel J, Rickerts V, Melichar V, Niemann N, Schwarz C. Aspergillus bronchitis in patients with cystic fibrosis. Mycopathologia 2018; 183 (01) 61-69
    CrossrefPubMedGoogle Scholar
  • 25 European Cystic Fibrosis Society. Accessed November 25, 2022 at: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports
    PubMedGoogle Scholar
  • 26 Hong G, Desai S, Moss RB, Eschenhagen P, Quon BS, Schwarz C. Clinician variability in the diagnosis and treatment of Aspergillus fumigatus-related conditions in cystic fibrosis: an international survey. J Cyst Fibros 2022; 21 (01) 136-142
    CrossrefPubMedGoogle Scholar
  • 27 Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130 (01) 222-226
    CrossrefPubMedGoogle Scholar
  • 28 Schwarz C, Brandt C, Whitaker P. et al. Invasive pulmonary fungal infections in cystic fibrosis. Mycopathologia 2018; 183 (01) 33-43
    CrossrefPubMedGoogle Scholar
  • 29 King J, Brunel SF, Warris A. Aspergillus infections in cystic fibrosis. J Infect 2016; 72 (suppl): S50-S55
    CrossrefPubMedGoogle Scholar
  • 30 Ryan PJ, Stableforth DE, Reynolds J, Muhdi KM. Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter. Thorax 1995; 50 (07) 809-810
    CrossrefPubMedGoogle Scholar
  • 31 Maguire CP, Hayes JP, Hayes M, Masterson J, FitzGerald MX. Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis. Thorax 1995; 50 (07) 805-806
    CrossrefPubMedGoogle Scholar
  • 32 Logan M, McLoughlin R, Gibney RG. Aspergilloma complicating cystic fibrosis. AJR Am J Roentgenol 1993; 161 (03) 674-675
    CrossrefPubMedGoogle Scholar
  • 33 Cohen-Cymberknoh M. Fungal infection and ABPA in CF. Paediatr Respir Rev 2013; 14: S34-S35
    PubMedGoogle Scholar
  • 34 Schwarz C, Hartl D, Eickmeier O. et al. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia 2018; 183 (01) 21-32
    CrossrefPubMedGoogle Scholar
  • 35 Scheffold A, Schwarz C, Bacher P. Fungus-specific CD4 T cells as specific sensors for identification of pulmonary fungal infections. Mycopathologia 2018; 183 (01) 213-226
    CrossrefPubMedGoogle Scholar
  • 36 Bacher P, Steinbach A, Kniemeyer O. et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med 2015; 191 (03) 348-352
    CrossrefPubMedGoogle Scholar
  • 37 Agarwal R, Chakrabarti A, Shah A. et al; ABPA Complicating Asthma ISHAM Working Group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43 (08) 850-873
    CrossrefPubMedGoogle Scholar
  • 38 Mastella G, Rainisio M, Harms HK. et al; Epidemiologic Registry of Cystic Fibrosis. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000; 16 (03) 464-471
    CrossrefPubMedGoogle Scholar
  • 39 Stevens DA, Moss RB, Kurup VP. et al; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (suppl 1): S225-S264
    CrossrefPubMedGoogle Scholar
  • 40 Nikolaizik WH, Weichel M, Blaser K, Crameri R. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165 (07) 916-921
    CrossrefPubMedGoogle Scholar
  • 41 Fricker-Hidalgo H, Coltey B, Llerena C. et al. Recombinant allergens combined with biological markers in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Clin Vaccine Immunol 2010; 17 (09) 1330-1336
    CrossrefPubMedGoogle Scholar
  • 42 Li BCM, Huh SM, Prieto MD. et al. Biomarkers for the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021; 9 (05) 1909-1930.e4
    CrossrefPubMedGoogle Scholar
  • 43 Schwarz C, Brandt C, Melichar V. et al. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. J Cyst Fibros 2019; 18 (02) 227-232
    CrossrefPubMedGoogle Scholar
  • 44 Schwarz C, Eschenhagen P, Bouchara JP. Emerging fungal threats in cystic fibrosis. Mycopathologia 2021; 186 (05) 639-653
    CrossrefPubMedGoogle Scholar
  • 45 Marchiori E, Zanetti G, Hochhegger B, Irion KL, Carvalho ACP, Godoy MCB. Reversed halo sign on computed tomography: state-of-the-art review. Lung 2012; 190 (04) 389-394
    CrossrefPubMedGoogle Scholar
  • 46 Hussien A, Lin CT. CT findings of fungal pneumonia with emphasis on aspergillosis. Emerg Radiol 2018; 25 (06) 685-689
    CrossrefPubMedGoogle Scholar
  • 47 Bacher P, Scheffold A. Flow-cytometric analysis of rare antigen-specific T cells. Cytometry A 2013; 83 (08) 692-701
    CrossrefPubMedGoogle Scholar
  • 48 Bacher P, Schink C, Teutschbein J. et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol 2013; 190 (08) 3967-3976
    CrossrefPubMedGoogle Scholar
  • 49 Jenks JD, Prattes J, Frank J. et al. Performance of the bronchoalveolar lavage fluid Aspergillus galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study. Clin Infect Dis 2021; 73 (07) e1737-e1744
    CrossrefPubMedGoogle Scholar
  • 50 Hoenigl M, Egger M, Boyer J, Schulz E, Prattes J, Jenks JD. Serum lateral flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: a two-centre mixed cohort study. Mycoses 2021; 64 (10) 1197-1202
    CrossrefPubMedGoogle Scholar
  • 51 Egger M, Penziner S, Dichtl K. et al. Performance of the Euroimmun Aspergillus antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. J Clin Microbiol 2022; 60 (04) e0021522
    CrossrefPubMedGoogle Scholar
  • 52 Williams C, Ranjendran R, Ramage G. Pathogenesis of fungal infections in cystic fibrosis. Curr Fungal Infect Rep 2016; 10 (04) 163-169
    CrossrefPubMedGoogle Scholar
  • 53 Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2015; 70 (03) 270-277
    CrossrefPubMedGoogle Scholar
  • 54 Grehn C, Eschenhagen P, Temming S, Düesberg U, Neumann K, Schwarz C. Frequent pet contact as risk factor for allergic bronchopulmonary aspergillosis in cystic fibrosis. Front Cell Infect Microbiol 2021; 10: 825
    CrossrefPubMedGoogle Scholar
  • 55 Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41 (02) 164-170
    CrossrefPubMedGoogle Scholar
  • 56 Fayon M, Corvol H, Chiron R, Bui S. le Groupe de Travail Inflammation de la Société Française de la Mucoviscidose. [National consensus regarding the prescription of inhaled corticosteroids in cystic fibrosis]. Arch Pediatr 2014; 21 (01) 88-94
    PubMedGoogle Scholar
  • 57 Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2016; 11 (11) CD002204
    PubMedGoogle Scholar
  • 58 Hennig S, Waterhouse TH, Bell SC. et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63 (04) 438-450
    CrossrefPubMedGoogle Scholar
  • 59 Brüggemann RJ, Alffenaar JW, Blijlevens NM. et al; Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48 (10) 1441-1458
    CrossrefPubMedGoogle Scholar
  • 60 Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49 (05) 503-507
    CrossrefPubMedGoogle Scholar
  • 61 Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2021; 9 (09) CD010288
    PubMedGoogle Scholar
  • 62 Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 3 (03) CD010288
    PubMedGoogle Scholar
  • 63 Schwarz C, Müller T, Lau S, Parasher K, Staab D, Wahn U. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatr Allergy Immunol 2018; 29 (01) 28-33
    CrossrefPubMedGoogle Scholar
  • 64 McElvaney G. What role do fungi play in CF lung disease?. Pediatr Pulmonol 2013
    PubMedGoogle Scholar
  • 65 Agache I, Rocha C, Beltran J. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75 (05) 1043-1057
    CrossrefPubMedGoogle Scholar
  • 66 Agache I, Beltran J, Akdis C. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75 (05) 1023-1042
    CrossrefPubMedGoogle Scholar
  • 67 Bacher P, Hohnstein T, Beerbaum E. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans . Cell 2019; 176 (06) 1340-1355.e15
    CrossrefPubMedGoogle Scholar
  • 68 Tsai A, Wu SP, Haseltine E. et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor/tezacaftor/ivacaftor. Pulm Ther 2020; 6 (02) 275-286
    CrossrefPubMedGoogle Scholar
  • 69 Ruhnke M, Cornely OA, Schmidt-Hieber M. et al. Treatment of invasive fungal diseases in cancer patients - revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses 2020; 63 (07) 653-682
    CrossrefPubMedGoogle Scholar
  • 70 Prigitano A, Esposto MC, Biffi A. et al. Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy. J Cyst Fibros 2017; 16 (01) 64-69
    CrossrefPubMedGoogle Scholar
  • 71 Risum M, Hare RK, Gertsen JB. et al. Azole-resistant Aspergillus fumigatus among Danish cystic fibrosis patients: increasing prevalence and dominance of TR34/L98H. Front Microbiol 2020; 11: 1850
    CrossrefPubMedGoogle Scholar
  • 72 Hong G, White M, Lechtzin N. et al. Fatal disseminated Rasamsonia infection in cystic fibrosis post-lung transplantation. J Cyst Fibros 2017; 16 (02) e3-e7
    CrossrefPubMedGoogle Scholar
  • 73 Hamprecht A, Morio F, Bader O, Le Pape P, Steinmann J, Dannaoui E. Azole resistance in Aspergillus fumigatus in patients with cystic fibrosis: a matter of concern?. Mycopathologia 2018; 183 (01) 151-160
    CrossrefPubMedGoogle Scholar
  • 74 Bentley S, Davies JC, Carr SB, Balfour-Lynn IM. Combination antifungal therapy for Scedosporium species in cystic fibrosis. Pediatr Pulmonol 2020; 55 (08) 1993-1995
    CrossrefPubMedGoogle Scholar
  • 75 Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L. et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans . Antimicrob Agents Chemother 2008; 52 (03) 1136-1139
    CrossrefPubMedGoogle Scholar
  • 76 Shah AV, McColley SA, Weil D, Zheng X. Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. J Clin Microbiol 2014; 52 (06) 2242-2244
    CrossrefPubMedGoogle Scholar
  • 77 Kröner C, Kappler M, Grimmelt AC, Laniado G, Würstl B, Griese M. The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients - clinical analysis of Trichosporon positive patients in a Munich cohort. BMC Pulm Med 2013; 13: 61
    CrossrefPubMedGoogle Scholar
  • 78 Yang YL, Liu YW, Chen HT, Tsai MS, Chu WL, Lo HJ. Genotype analysis based on intergenic spacer 1 sequences of Trichosporon asahii collected in Taiwan. Med Mycol 2013; 51 (08) 880-883
    CrossrefPubMedGoogle Scholar
  • 79 Navarro J, Rainisio M, Harms HK. et al; European Epidemiologic Registry of Cystic Fibrosis. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. Eur Respir J 2001; 18 (02) 298-305
    CrossrefPubMedGoogle Scholar
  • 80 Chotirmall SH. Candida albicans in cystic fibrosis: “opening statements presented, let the trial begin”. Pediatr Pulmonol 2016; 51 (05) 445-446
    CrossrefPubMedGoogle Scholar
  • 81 Hector A, Kirn T, Ralhan A. et al. Microbial colonization and lung function in adolescents with cystic fibrosis. J Cyst Fibros 2016; 15 (03) 340-349
    CrossrefPubMedGoogle Scholar
  • 82 Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus . Philos Trans R Soc Lond B Biol Sci 2016; 371 (1709): 20150460
    CrossrefPubMedGoogle Scholar
  • 83 Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 2017; 17 (12) e383-e392
    CrossrefPubMedGoogle Scholar
  • 84 Mourad A, Perfect JR. Tolerability profile of the current antifungal armoury. Accessed November 25, 2022 at: https://academic.oup.com/jac/article/73/suppl_1/i26/4769698
    PubMedGoogle Scholar
  • 85 Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of azole antifungals in cystic fibrosis. Mycopathologia 2018; 183 (01) 139-150
    CrossrefPubMedGoogle Scholar
  • 86 King JA, Nichols AL, Bentley S, Carr SB, Davies JC. An update on CFTR modulators as new therapies for cystic fibrosis. Paediatr Drugs 2022; 24 (04) 321-333
    CrossrefPubMedGoogle Scholar
  • 87 Hoenigl M, Sprute R, Egger M. et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021; 81 (15) 1703-1729
    CrossrefPubMedGoogle Scholar